Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 751-761

  Lane, Stephanie R ^a,b,c   Nanda, Prasanta ^a   Rold, Tammy L ^a   Sieckman, Gary L ^b   Figueroa, Said D ^a,b   Hoffman, Timothy J ^a,b,c   Jurisson, Silvia S ^c   Smith, Charles J ^a,b,c  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Bombesin; Copper 64; Gastrin releasing peptide; Prostate cancer

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(4 AMINOBENZOIC ACID)BOMBESIN[7-14]AMIDE CU 64; 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(5 AMINOVALERIC ACID)BOMBESIN[7-14]AMIDE CU 64; 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(6 AMINOHEXANOIC ACID)BOMBESIN[7-14]AMIDE CU 64; 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(8 AMINOOCTANOIC ACID)BOMBESIN[7-14]AMIDE CU 64; 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(9 AMINONANOIC ACID)BOMBESIN[7-14]AMIDE CU 64; 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID(BETA ALANINE)BOMBESIN[7-14]AMIDE CU 64; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BIOASSAY; CANCER SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGE QUALITY; IN VIVO STUDY; ISOTOPE LABELING; ISOTOPE TRACING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PROSTATE CANCER; SCID MOUSE; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT; WHOLE BODY TOMOGRAPHY;

ANIMALS; BOMBESIN; COPPER RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956985437     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.04.016     Document Type: Article

References (36)

1. Cancer facts and figures 2009 2009, American Cancer Society, American Cancer Society, Atlanta.
2. Koppán M., Nagy A., Schally A.V., Plonowski A., Halmos G., Arencibia J.M., et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. The Prostate 1999, 38:151-158.
3. Carducci M., DeWeese T., Nelson W., Simons J., Sinibaldi V., Eisenberger M. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin Oncol 1996, 23:56-62.
4. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
5. Sun B., Halmos G., Schally A.V., Wang X., Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. The Prostate 2000, 42:295-303.
6. 64Cu-labeled bombesin analogue. Bioconjugate Chem 2003, 14:756-763.
7. Fleischmann A., Läderach U., Friess H., Buechler M., Reubi J. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 2000, 80:1807-1817.
8. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007, 104:12462-12467.
9. 2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009, 36:171-181.
10. Wadas T.J., Wong E., Weisman G.R., Anderson C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007, 13:3-16.
11. Hoffman T.J., Smith C.J. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol 2009, 36:579-585.
12. Franciscus Wilhelmus Nijsen J., Cornelis Krijger G., Dirk van het Schip A. The bright future of radionuclides for cancer therapy. Anti-Cancer Agents Med Chem 2007, 7:271-290.
13. Anderson C.J., Welch M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999, 99:2219-2234.
14. Blower P.J., Lewis J.S., Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996, 23:957-980.
15. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47:1465-1474.
16. Jones-Wilson T.M., Deal K.A., Anderson C.J., McCarthy D.W., Kovacs Z., Motekaitis R.J., et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 1998, 25:523-530.
17. Sun X., Wuest M., Weisman G.R., Wong E.H., Reed D.P., Boswell C.A., et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002, 45:469-477.
18. Bartolo N.M.D., Sargeson A.M., Donlevy T.M., Smith S.V. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc, Dalton Trans 2001, 2303-2309.
19. 64Cu-labeling, and bioconjugation of a new bis(2-pyridylmethyl) derivative of 1,4,7-triazacyclononane. Bioconjugate Chem 2008, 19:719-730.
20. Pippin C.G.K.K., Mirzadeh S., Gansow O.A. Kinetics of the isotopic exchange between copper(II) and copper(II) 1,4,7-triazacyclononane-N,N',N' triacetate. J Labelled Compd Radiopharm 1991, 30:221.
21. Meares C.F. Capturing copper for molecular imaging and therapy. Recent Advances of Bioconjugation Chemistry in Molecular Imaging 2008, 227-241. Research Signpost, Kerala, India. X. Chen (Ed.).
22. i) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
23. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33:371-380.
24. Montet X., Weissleder R., Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjugate Chem 2006, 17:905-911.
25. Van der Merwe M.J., Boeyens J.C.A., Hancock R.D. Crystallographic and thermodynamic study of metal ion size selectivity in the ligand 1,4,7-triazacyclononane-N,N',N'-triacetate. Inorg Chem 1985, 24:1208-1213.
26. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
27. 2: an in vitro/in vivo structure-activity relationship study where X= 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjugate Chem 2002, 14:93-102.
28. 2 structural paradigm in a prostate cancer model. Bioconjugate Chem 2008, 19:1803-1812.
29. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006, 47:1144-1152.
30. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007, 48:1327-1337.
31. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11:2785-2808.
32. Rakesh K., Hongming Z., Abass A. PET in the management of urologic malignancies. Radiol Clin North Am 2004, 42:1141-1153.
33. Hofer C., Laubenbacher C., Block T., Breul J., Hartung R., Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999, 36:31-35.
34. 18F-fluorine. J Nucl Med 2010, 51:454-461.
35. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
36. 64Cu-NO2A-bombesin antagonist and agonist ligands. Nucl Med Biol 2010, [submitted].